Podcast appearances and mentions of randy schekman

Chad and Mike invite Nobel Laureate Dr. Randy Schekman to discuss his research into yeast cells and the mechanisms that yeast (and human) cells use to direct traffic. Proteins that are created within the cell need to be pushed into the appropriate places and Schekman is one of the discoverers of those mechanisms.Enjoy these episodes ad free!

Jorge Fontevecchia en entrevista con el biólogo celular e investigador científico estadounidense, ganador del Premio Nobel de Medicina 2013

"Foolish consistency is a hobgoblin of a little mind" Ralph Waldo Emerson   If you like what you hear and you want to support me you can make a one time donation using PayPal https://paypal.me/beinganddoing.  In this episode I am talking to a person who has harvested the highest accolades in his profession, from looking at pond scum under the microscope he arrived to the Nobel prize. Yet what he still enjoys the most is the "simple" act of gathering and analysing data in biology. A gentle reminder that genuine curiosity about the world can takes us further than we can imagine. We dive into several topics that are giving headaches to contemporary researchers. One of them is the challenge of scientific publishing which you have already heard something about in the previous episode. We also talk about incentives in science and how we can have different working models that promote cooperation rather than competition. In other words how to be a good citizen of science. Finally, we touch upon on how making mistakes and being brave enough to accept them is a normal and a very human part of our life journeys.    Dr. Randy Schekman is a professor of molecular and cell biology at UC Berkeley. He has been awarded the 2013 Nobel Prize in Physiology and medicine for his ground breaking work on cell membrane vesicle trafficking. Currently his lab is devoted to molecular description of this process in new coriat excels professor Sheckman also coordinates the research initiative dubbed ASAP to advance targeted basic research and resources to uncover the roots of Parkinson's disease it is one of the pioneers and supporters of open access scientific publishing. I hope this conversation showcases the complexity of the scientific endavour and brings to your awarness the current stuggles and challenges we are facing.  If you like what you hear please share, like and subscribe so these stories can reach more people.⁠ Find all the links in one place: https://linktr.ee/being_and_doing Connect with Being and Doing: Facebook: https://www.facebook.com/beinganddoing.podcast Instagram: https://www.instagram.com/being_and_doing/ Twitter: https://twitter.com/beinganddoing_p Newsletter: https://crafty-trader-7519.ck.page/68feebc101 Sounder.fm: https://beinganddoing.sounder.fmSpotify: https://open.spotify.com/show/05UVsrG... Apple podcasts: https://podcasts.apple.com/us/podcast... Google podcasts: https://podcasts.google.com/feed/aHR0... Stitcher: https://www.stitcher.com/podcast/bein... This podcast represents my own and my guests views and opinions. The content here should not be taken as medical, financial or any other advice. The content is for informational purposes only, and because each person is so unique, please consult the appropriate professional for any specific questions you have. Thank you for joining me on this journey

Jorge Fontevecchia en entrevista con el biólogo celular, investigador científico y Premio Nobel de Medicina 2013.

David Baker is the director of the Institute for Protein Design, a Howard Hughes Medical Institute Investigator, the Henrietta and Aubrey Davis Endowed Professor in Biochemistry, and an adjunct professor of genome sciences, bioengineering, chemical engineering, computer science, and physics at the University of Washington. His research group is focused on the design of macromolecular structures and functions.He received his Ph.D. in biochemistry with Randy Schekman at the University of California, Berkeley, and did postdoctoral work in biophysics with David Agard at UCSF. Baker has received awards from the National Science Foundation, the Beckman Foundation, and the Packard Foundation. He is the recipient of the Breakthrough Prize in Life Sciences, Irving Sigal and Hans Neurath awards from the Protein Society, the Overton Prize from the ISCB, the Feynman Prize from the Foresight Institute, the AAAS Newcomb Cleveland Prize, the Sackler prize in biophysics, and the Centenary Award from the Biochemical society. Sixty-five of his mentees have gone on to independent faculty positions, he has published over 500 research papers, been granted over 100 patents, and co-founded 13 companies.Baker is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. He is also a project leader with The Audacious Project.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Tony O'Rourke VP Strategic Partnerships provides an overview of the Enago See The Future 2021.  This conference features Nobel Laureate Dr. Randy Schekman and many other great speakers.

The scientific method remains the best systematic approach we have been able to develop in our ongoing endeavor to advance human flourishing. But that does not mean it's perfect - indeed, it probably never will be. But what are the ways in which we can make science better? Perhaps some of the most fundamental ways lie in the process of publishing research findings. This applies to biodiversity science as much as it does to other scientific disciplines. Randy Schekman joins me to pick apart some of the well-known and less well-known critiques of the scientific publication process, including the role of hype. Randy is a cell biologist, Nobel Prize winner, and previous editor-in-chief of PNAS, Annual Review of Cell Developmental Biology, and eLife. He is based at the University of California, Berkeley, where he has spent almost his entire career.01:57:  How biodiversity got Randy interested in science07:37:  How and why we publish scientific research11:50:  Domination by commercial journals17:22:  The introduction of impact factor, and its flaws21:12:  Professional editors and other problems with "luxury journals" 26:59:  The pressure to publish in big journals, and its societal implications28:11:  The problem with not publishing negative results34:41:  What's changed since Randy began his crusade in 2013?38:03:  What can we do about it?43:30:  What's the alternative to impact factor?Visit www.case4conservation.com

Episode 145 welcomes Jeremy Streich, author of The Tree of Knowledge by New Degree Press. He is a startup founder and 2019 iTunes Top 100 podcaster having interviewed New York Times Best-selling Author Michael Pollan, Presidential Candidate Andrew Yang, Nobel Prize biologist Randy Schekman, Chicago's Treasurer Kurt Summers, and more.Find Jeremy Online:Tree of Knowledge Book - https://www.amazon.com/Tree-Knowledge-J-F-Streich/dp/1641379413/ref=tmm_pap_swatch_0?_encoding=UTF8&qid=1602187804&sr=8-1Newsletter: https://jeremystreich.substack.com/Website: https://www.jeremyfstreich.com/Linkedin: https://www.linkedin.com/in/jeremyfstreich/Twitter: https://twitter.com/jeremyfstreichInstagram: https://www.instagram.com/jeremy.streich/Facebook: https://www.facebook.com/jeremy.streich/Medium: https://medium.com/@jeremystreichAbout Jeremy:Jeremy Streich is the author of The Tree of Knowledge New Degree Press. He is a startup founder and 2019 iTunes Top 100 podcaster having interviewed New York Times Best-selling Author Michael Pollan, Presidential Candidate Andrew Yang, Nobel Prize biologist Randy Schekman, Chicago's Treasurer Kurt Summers, and more...Since his twelfth birthday, Jeremy has spent time in 25 countries, interviewing thinkers from around the world on topics of life, neuroscience, and ancient philosophy—all of which help Jeremy build not-so-far-fetched worlds of his imagination.When not writing, Streich is probably on a hike or is striking out at stand-up comedy, dating, dead-lifting, and investing.........Thank you for listening!I’d appreciate a 5-star review on Apple Podcasts if you believe I’ve earned it. - Leave a ReviewFollow the Just Get Started Podcast:Instagram at https://www.instagram.com/justgetstartedpodcastFacebook https://www.facebook.com/justgetstartedpodcastLearn more about the host, Brian OndrakoBrian's Now Page: https://www.brianondrako.com/now/Brian's Instagram @brianondrakoBrian's Twitter @brianondrakoBrian's Linkedin: https://www.linkedin.com/in/brianondrako/ See acast.com/privacy for privacy and opt-out information.

Schekman outlines exosome biogenesis. Exosomes are extracellular vesicles released by the cell, and in contrast to intracellular vesicles, exosomes contain small molecules of RNA. Schekman's laboratory characterized the RNAs contained in exosomes and showed the importance of Ybx1 protein for the recruitment of certain miRNAs into exosomes.

Schekman explains how his laboratory used baker's yeast to uncover major proteins involved in the secretory pathway, and describes proteins involved in budding, vesicle trafficking, and vesicle fusion.  Schekman also presents data from his laboratory that helped to identify the ER channel through which proteins enter the secretory pathway. These series of experiments show how, step by step, scientific knowledge evolves, uncovering the fundamental mechanisms to better understand human disease.

Dr. Randy Schekman overviews the secretory pathway and reviews historical experiments that shaped our molecular understanding of this pathway. The journey begins at the endoplasmic reticulum (ER), where proteins that engage the secretory pathway get translated. The mRNA of these proteins codes for a signal sequence that serves as a “tag” to bring the mRNA-ribosome-newly-synthesized protein to the ER for continued translation and movement of the new secretory protein across the ER membrane into the interior or lumen of the organelle. Vesicles transport the recently translated proteins to the Golgi Apparatus, where they get “packaged” and sent to their final destination.

Episode Notes Guest-hosting this mini-episode is my lovely niece, Amber Magaña. Amber sought to answer the question, "How is biotechnology being used to battle COVID-19?" To answer this question, she got in touch with the 2013 Nobel Laureate of Medicine and Physiology, Dr. Randy Schekman. Dr. Schekman is a professor at the University of California, Berkeley, where he has long focused his research in the field of molecular and cell biology.

On Sept. 17, UC Berkeley hosted the second annual Aging, Research, and Technology Innovation Summit, a daylong event that brought together researchers, entrepreneurs, policymakers and health care workers to tackle some of the biggest questions in aging research. This year’s summit focused on the challenge of understanding and treating neurodegenerative diseases.Randy Schekman, a professor of molecular and cell biology at UC Berkeley, won the 2013 Nobel Prize in physiology or medicine. He spoke at the summit about Parkinson's disease — what we already know about the disease and new research efforts that are underway."We have experienced a pandemic in Parkinson's disease," he told the audience. "The incidence ... is increasing dramatically in spite of the fact that the disease was first recognized and reported by clinical symptoms 200 years ago. As the population inexorably ages, we are experiencing a wave of this disease which inexorably takes the lives of those who are afflicted."Schekman, whose wife died from the disease two years ago, went on to describe a new collaborative research initiative — Aligning Science Across Parkinson's (ASAP). Led by Schekman, ASAP was created by the Milken Institute Center for Strategic Philanthropy with support from the Sergey Brin Family Foundation to better understand the underlying causes of Parkinson's disease."We want to know where the disease begins, what the molecules and cells and neural circuits that are affected primarily by the disease, and then how it progresses," he said. "Much of the research that gone on in the clinic has been valuable and important, but there are no cures. ... Many of us feel that what we really need to do is get into the laboratory to understand these basic processes."ASAP's first journal article, "Point of View: Coordinating a new approach to basic research into Parkinson's disease," was published on Sept. 25 in the open-access journal, eLife.Listen and read the transcript on Berkeley News. See acast.com/privacy for privacy and opt-out information.

Randy Schekman, the PNAS Editor-in-Chief, discusses the selection process and history of the Cozzarelli Prize. The Cozzarelli Prize is given annually to six outstanding PNAS articles, each representing one of the major disciplines of the National Academy of Sciences.

Biologist Professor Randy Schekman received the Nobel Prize in Physiology or Medicine in 2013, along with colleagues, for his work on cell membrane vesicle trafficking - a major transport system within our cells. A passionate advocate of the scientific method and open-access journals, Professor Schekman argues that science needs to be vocally defended now, more than ever. Episode recorded: September 19, 2018. Interviewer: Dr Andi Horvath. Producer and editor: Chris Hatzis. Co-production: Dr Andi Horvath and Silvi Vann-Wall. Banner image: Shutterstock

In this episode of the eLife podcast, the neuroscience of chewing, African sleeping sickness, skin cancer, and an ancient protein complex called TSET. eLife editor-in-chief Randy Schekman also shares his thoughts on scientific publishing... Get the references and the transcripts for this programme from the Naked Scientists website

Dr. Randy Schekman is a professor of molecular and cell biology at the University of California, Berkeley. In 2013, he shared the Nobel Prize for Physiology or Medicine for his role in revealing the machinery that regulates the transport and secretion of proteins in human cells. A former editor-in-chief of Proceedings of the National Academy of Sciences, he currently serves as editor-in-chief of the open-access journal eLife, which publishes the most important advances in the life and biomedical sciences. He was elected to the National Academy of Sciences and his prestigious honors include receiving the Albert Lasker Award for Basic Medical Research. Dr. Schekman obtained his doctorate from Stanford University where he worked with Dr. Arthur Kornberg, another Nobel laureate. Along with his tremendous achievements in the realm of science, Dr. Schekman is a strong advocate of the importance of public research universities and public education. As a result, he donated his Nobel Prize money to the Berkeley campus in order to create an endowed chair in the life sciences. In this interview, Dr. Schekman discusses his amazing story of getting his first grant "trashed" but then finding his way to researching baker's yeast and moving into genetics and protein exporting mechanisms. Other topics include translational medicine and the NIH, how his research led to insulin production and hepatitis surface antigen, and George Palade, another Nobel laureate.

This week we talk to Randy Schekman, the University of California-Berkeley cell biologist who was just awarded the 2013 Nobel Prize in medicine for his work on how cells regulate the protein “traffic” that is at the core of their communication with other cells.In the interview with co-host Indre Viskontas, Schekman not only explains his scientific breakthroughs—he also tells us why he wants to take a stand about the steeply rising cost of public higher education, which is driving huge student debt loads and rendering college simply too expensive for some. Affordable higher education, says Schekman, is “really in peril all over the country."In addition to being a Nobel laureate, Schekman is also a winner of the coveted Albert Lasker Award for Basic Medical Research, a member of the National Academy of Sciences, and the former editor-in-chief of the Proceedings of the National Academy of Sciences.This episode also features a (spoiler free) discussion of the science behind the hit sci-fi movie Gravity, and the controversy this year over the Nobel Prize in physics.Subscribe:itunes.apple.com/us/podcast/inquiring-minds/id711675943feeds.feedburner.com/inquiring-minds

Randy Schekman, the PNAS Editor-in-Chief, discusses the selection process and history of the Cozzarelli Prize. The Cozzarelli Prize is given annually to six outstanding PNAS articles, each representing one of the major disciplines of the National Academy of Sciences.